Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Lacombe

Showing results (71-80 of 118) with videos related to

Pageof 12
Sort By:
Neuro-Oncology|September 20, 2013
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trialsThierry Gorlia, Wenting Wu, Meihua Wang, et al.
The Lancet. Oncology|March 3, 2022
Code of practice needed for samples donated by trial participantsRobert Coleman, Arlene Chan, Carlos Barrios, et al.
The Lancet. Oncology|December 18, 2007
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Thierry Gorlia, Martin J van den Bent, Monika E Hegi, et al.
Neuro-Oncology|October 24, 2012
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastomaEnrico Franceschi, Roger Stupp, Martin J van den Bent, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Molecular Oncology|November 1, 2019
Towards a Cancer Mission in Horizon EuropeAnton Berns, Ulrik Ringborg, Alexander Eggermont, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 7, 2026
Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the EORTC-ESTRO radiotherapy infrastructure for Europe (E<sup>2</sup>-RADIatE) projectYolande Lievens, Damien C Weber, Nicolaus Andratschke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trialRené-Olivier Mirimanoff, Thierry Gorlia, Warren Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 TrialsJohan M Kros, Karin Huizer, Aurelio Hernández-Laín, et al.
Pageof 12

Showing results (71-80 of 118) with videos related to

Sort By:
Pageof 12
Neuro-Oncology|September 20, 2013
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trialsThierry Gorlia, Wenting Wu, Meihua Wang, et al.
The Lancet. Oncology|March 3, 2022
Code of practice needed for samples donated by trial participantsRobert Coleman, Arlene Chan, Carlos Barrios, et al.
The Lancet. Oncology|December 18, 2007
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3Thierry Gorlia, Martin J van den Bent, Monika E Hegi, et al.
Neuro-Oncology|October 24, 2012
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastomaEnrico Franceschi, Roger Stupp, Martin J van den Bent, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Molecular Oncology|November 1, 2019
Towards a Cancer Mission in Horizon EuropeAnton Berns, Ulrik Ringborg, Alexander Eggermont, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international surveyXavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 7, 2026
Leveraging the potential of prospective registries for radiation oncology research: 5-year experience from the EORTC-ESTRO radiotherapy infrastructure for Europe (E<sup>2</sup>-RADIatE) projectYolande Lievens, Damien C Weber, Nicolaus Andratschke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2006
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trialRené-Olivier Mirimanoff, Thierry Gorlia, Warren Mason, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2015
Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 TrialsJohan M Kros, Karin Huizer, Aurelio Hernández-Laín, et al.
Pageof 12